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INTRODUCTION:  Giant  pancreatic  insulinomas  are  rare  endocrine  tumors.  We  describe  2 cases  reviewing
the  current  literature.
PRESENTATION  OF  CASE:  We  report  herein  2 female  patients  affected  by giant  insulinomas  of  14  cm and
6  cm,  respectively.  Symptomatic  hypoglycemia  episodes  occurred  during  4 months  in ﬁrst  case  and  3
years  in the  second  one until  diagnosis.  Both  patients  were  successfully  treated  performing  a  distal
pancreatectomy  with  splenic  preservation  in  the  ﬁrst case and  a  Whipple’s  procedure  in  the second  one.euroendocrine tumor
DISCUSSION:  Up  to  now  only  7 cases  have  been  reported  previously.  Insulinomas  larger  than  3  cm  accounts
for  less  than  5% of  all.  This  literature  review  shows  that despite  the  size  hypoglycemic  symptoms  varies
from  1 day  to 3  years  and only  1 out  of 9  cases  reported  presented  lymph  nodes  metastases.  No recurrences
have  been  described.
CONCLUSION:  One  of  the  cases  here  described  (14 cm)  is  the  largest  presented  in  the  literature.  Despite
the  size,  giant  insulinoma  is  related  apparently  neither  to metastases  nor  to the  recurrences.
gical © 2012 Sur
. Introduction
Insulinomas are rare tumors and most of them small at the time
f diagnosis (less than 3 cm).1 The disease usually presents with
linical manifestation of hypoglycemia, secondary to inappropri-
te insulin secretion.2 Only few cases of giant insulinomas have
een reported up to now.3–9 We  report two more cases of giant
nsulinomas describing herein its characteristics and treatment. A
eview of the literature is performed.
. Case reports
.1.  Case 1
A  57-year-old female was attended in the emergency depart-
ent with an acute-onset low consciousness level, sudden
onfusion, abnormal movements and inability to recognize her
elatives. She had been studied up to three times during the pre-
ious 4 months for similar episodes. Laboratory tests showed
erum glucose of 24 mg/dl. Symptoms immediately disappeared
fter intravenous infusion of glucose. Serum hormones values
ere: insulin 22 units/mL, C-peptide 3.3 ng/mL, intact proinsulin
9.3 pmol/L. Thoracic-abdominal-pelvic CT was performed (Fig. 1).
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Ultrasound-guided ﬁne-needle biopsy was suggestive for a neu-
roendocrine tumor like. Octreoscan study conﬁrmed a contrast
uptake by the tumor. A distal pancreatectomy with splenic preser-
vation was performed (Fig. 2) and the patient was discharged on
8th postoperative day without complications. Pathological exam
revealed a 14 cm × 10 cm × 6 cm mass identiﬁed as a neuroen-
docrine tumor (Fig. 3). Immunohistochemical staining revealed
positivity for insulin and chromogranine. Nuclear proliferation
index Ki-67 was higher than 20%. A poorly differentiated and
functioning endocrine carcinoma was  ﬁnally reported. The patient
remains asymptomatic and without tumoral recurrence after six
years of follow-up.
2.2.  Case 2
A  63-year-old woman was referred to emergency department
with sudden lumbar pain and anxiety. The patient had a history of
several hypoglycemic symptoms in the last years. On  admission,
laboratory tests showed a serum glucose level of 45 mg/dl, insulin
28 units/mL, C-peptide 3.8 ng/mL, intact proinsulin 63.2 pmol/L.
CT  scan revealed a mass sized 8 mm × 6 mm × 6.5 mm in the
pancreatic head, solid without cystic component and slightly
heterogeneous with central calciﬁcation. PET-CT study showed
increased uptakes in the head of the pancreas (SUV: 38.97). Eco-
Open access under CC BY-NC-ND license.endoscopy showed a solid giant mass with high vascularization
close to the common bile duct and the Wirsung and biopsy was
compatible with neuroendocrine tumor. Octreoscan study was
normal.
NC-ND license.
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Surgical resection was planned ﬁnding a unifocal tumor in the
ead of pancreas (Fig. 2). A standard pancreaticoduodenectomy
Whipple’s procedure) was performed. The pathology report a
umor of 8 cm with cells that were all positive by immunohisto-
hemical staining for the neuroendocrine marker synaptophysin
Fig. 3). Amyloid was present approximately in the 60% of
umor volume. Immunohistochemical stains for insulina, gastrin,
lucagon and chromogranin were all negative. The marker ki-
7 < 20% and 4 mitosis for 10 high-power ﬁelds were observed.
herefore, it was classiﬁed as a well-differentiated neuroendocrine
umor. Her postoperative course was uneventful and she was
ismissed on the 10th postoperative day. Her insulin, proinsulin
nd C-peptide levels returned normal. Currently the patient is
symptomatic with no evidence of recurrence at 11 months of
ollow up.
Fig. 2. Intraoperative ﬁnd in the pancreatic tail, without pathologic lymph nodes.
3. Discussion
Pancreatic endocrine tumors are rare with an incidence of 1–2
cases per million patients every year. The most common neuroen-
docrine tumor of pancreatic islet cell is insulinoma and the ﬁrst
report was  by Nicholls in 1902.10
There is a slightly higher frequency in women  and the mean
age of presentation is 45 years old, while patients with multiple
endocrine neoplasia type 1 (MEN 1) (5–10% of cases) occur at a
younger age.1 Our cases were slightly older.
The majority of these tumors are found to be solitary, equally
distributed throughout the pancreas. They are usually small, with
a mean size of 1.5 cm;  only 4% are larger than 3 cm.
The mechanism by which insulinomas maintain high levels of
insulin secretion in the presence of hypoglycemia is still unknown.
ings and specimens.
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As in the cases herein presented, clinical presentation consists
n symptoms related to hypoglycemia, which can be classiﬁed
n neuroglycopenic symptoms, most common, including anxi-
ty, dizziness, lightheadedness, confusion, visual changes, fatigue,
eizures and loss of consciousness and neurogenic signs and symp-
oms, such as palpitations, tremors and tachycardia.
In 1935, Whipple and Franz described a triad of clinical ﬁnd-
ngs that were unique to patients with insulinoma: symptoms of
ypoglycemia, a plasma glucose level of 45 mg/dl or less when
hey occurred, and relief of symptoms with the administration of
lucose.11 In addition, some authors1 emphasized recently that
oncomitant measurement of C peptide levels is mandatory for
stablishing a diagnosis of insulinoma.
The newly 2000 classiﬁcation, updated in 2010 of neuroen-
ocrine tumors was adopted by the World Health Organization
lassiﬁcation (WHO) for Pancreatic Endocrine Neoplasms.12
If giant insulinomas are easily localized because of their size,
pproximately 40% of all them are not localized preoperatively,
nd between 3% and 10% remain occult even after intraoperative
alpation and use of intraoperative ultrasound.10
Our routinely preoperative work up includes CT scan, PET scan
nd Eco-endoscopy; if a neuroendocrine tumor is suspected, an
ctreoscan is performed, too.
Surgical excision of insulinoma is the treatment of choice. It
onsists on a simple enucleation of the tumor or a distal partial pan-
reatectomy, if localized in the tail of the pancreas. More aggressive
urgical procedure is needed for larger tumors, requiring Whipple
r total pancreatectomy techniques. Laparoscopic surgery can be
erformed depending on surgeon experience and size of the tumor.
The recurrences can occur in 6% of cases and more common
n MEN  1 patients manifesting with recurrent hypoglycemia.1 It
uggests regrowth of residual insulinoma tissue left.
Insulin secreting carcinomas are potentially curable tumors
hen conﬁned to the pancreas and regional lymph nodes. In
ddition, we agree with aggressive resection of advanced neu-
oendocrine tumors due to proven excellent survival rates even in
resence of liver metastasis, lymph node involvement or vascular
ncasement,13 thanks to the slow-growing nature of these tumors. higher than 20%. (C) Microscopic lymphatic and vascular invasion was noted.
In cases where insulinoma was  missed during pancreatic explo-
ration, those who  are not candidate or refuse surgery, or who have
unresectable metastasic disease, medical therapy with diazoxide,
corticoids, glucagone or ocreotide can be the chosen treatment.14
Our literature review revealed only 7 previous reports of giant
insulinomas (Table 1) with a size ranging from 9 cm to 14 cm.3–9
We  present 2 more cases of exceptionally giant insulinoma, one
of them the largest reported in the literature up to now.
The time frame period of diagnosis of giant insulinoma reported
varies from 1 day to 3 years.
Therefore, we can postulate that giant insulinoma may  develop
from a non-functioning pancreatic mass that, over a period of years
start to have a sufﬁcient insulin secretion to cause hypoglycemic
symptoms.
Malignant behavior occurs in only 5 to 10% of cases and tra-
ditionally related to size (larger than 3 cm) and Ki67 index, with
evidence of gross local invasion or metastasis to the peripancreatic
lymph nodes and liver.12
Only one of the giant insulinomas reported had local lymph
nodes invasion without recurrence at 7 years of follow up.4 None of
these giant insulinomas presented metastasis at diagnosis, there-
fore, we can suppose that giant size might not be related to
malignancy.
According to the WHO  classiﬁcation for pancreatic endocrine
tumors, only 2 cases were classiﬁed as carcinoma (the ﬁrst 3 cases
described are not included in the WHO  classiﬁcation). Moreover,
our poorly differentiated carcinoma is still free from recurrence
after 6 years of follow up (Table 1).
In two cases (including one of the present) immunohisto-
chemical staining for insulin was negative, although patients had
resolution of hypoglycemic symptoms and normalization of labo-
ratory abnormalities; this result suggest that a small subset of this
large pancreatic mass could secrete insulin and that it might not
be included in the anatomo-pathological specimen section. In fact,
the case described by Mittendorf illustrates such situation, where
only 50% of tumor cells were positive for insulin.6
Amyloid is present up to 50% of insulinomas1; concerning giant
insulinomas reported, approximately up to 70% contain amyloid
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Table 1
Literature review of giant insulinoma.
Case Author Year Tumor size Duration of symptoms Metastases WHO  classiﬁcation MEN  Prognosis
1 Arensman 1976 10 cm 1 day NA NA
2 Danforth 1984 9 cm 7 months Lymph nodes NA 7 years
3 Kataoka 1999 11 cm 9 months NA I NA
4  Mittendorf 2005 9 cm 3 years Well differentiated endocrine tumor 6 months
5  Ketari 2009 11.5 cm Few months Well differentiated endocrine tumor NA
6  Sugiyama 2010 10 cm 3 months Well differentiated endocrine carcinoma NA
7  Oberheim 2011 13.5 cm 3 months Well differentiated endocrine tumor 1 year
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18 Present 1 2012 14 cm 4 months
9 Present 2 2012 6 cm 1 year 
A: not available.
ith the exception of the Oberheim case that did not contain a
ubstantial component.9 Investigators have postulated that giant
nsulinomas achieve their size because of overproduction and aber-
ant processing of islet amyloid polypeptide, which is secreted in
oncert with insulin from insulinoma cells.15
Favorable outcomes have been reported in 5 patients, includ-
ng the two present cases (the remaining 4 cases lack of this data)
ithout evidence of recurrence. In this review we found only one
atient that presented MEN  type I.5
. Conclusions
Giant pancreatic insulinomas are extremely rare tumors. Only
even cases have been reported previously and one of the two cases
erein presented is the largest reported up to now (14 cm). This
iterature review highlights that despite the size, they generally do
ot present metastases at the time of diagnosis. Treatment of choice
s surgical resection with complete remission of symptoms.
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